pharmaphorum

OCTOBER 10, 2022

For the 32 million individuals in the US with food allergies, more research into symptoms, causes, and treatments has been long sought after, but historically underfunded. per person being spent on food allergy research. Luckily for those with food allergies, the food allergy sector has benefitted from this influx of funding.

Compounding 109

Compounding Hospitals 109

STAT

SEPTEMBER 12, 2022

National Institutes of Health is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox, as current data on its effectiveness against the virus is limited , The Hill writes. The TPOXX was approved by the U.S.

246

246

Pharmaceutical Technology

FEBRUARY 7, 2024

Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.

75

75

RX Note

APRIL 2, 2024

Introduction Contrast allergy is an immunologic and clinical reaction appearing hours to days after administration of iodinated or gadolinium-based contrast media. Betadine) allergies are at no greater risk from iodinated contrast medium than are patients with other allergies (i.e., neither is a significant risk factor).

52

52

Pharmaceutical Technology

FEBRUARY 19, 2024

Allergen for Peanut Allergy is under clinical development by ALK-Abello and currently in Phase II for Peanut Allergy.

40

40

ALiEM - Pharm Pearls

NOVEMBER 10, 2023

Clin Rev Allergy Immunol. Copyright Images and cases from the Society of Academic Emergency Medicine (SAEM) Clinical Images Exhibit at the 2023 SAEM Annual Meeting | Copyrighted by SAEM 2023 – all rights reserved. View other cases from this Clinical Image Series on ALiEM. South Med J. 2014 Nov;107(11):724-7.

158

158

RX Note

NOVEMBER 4, 2023

Ideally, infant formula should be given to an infant only when there is a medical indication such as clinical evidence of insufficient intake (especially excessive weight loss) or the mother is infected HIV or has active tuberculosis. Use of soy formulas in patients with cow milk protein allergy is controversial.

52

52

RX Note

MARCH 30, 2023

NOTE: People often confuse alcohol intolerance and alcohol allergy, but they are not the same condition. Alcohol allergy is an immune system response. severe allergy) should consult with a doctor. Alcohol intolerance is not the same as being intoxicated or drunk. People who experience serious reaction (e.g.

Mayo Clinic 40

Mayo Clinic Immunity Immunization Community Pharmacies 40

Pharmaceutical Business Review

DECEMBER 20, 2023

LimmaTech intends to commence Phase I clinical trials for the vaccine candidate in 2024, with the option to secure complete worldwide rights post the trial’s outcome. Preclinical trials conducted in rabbits and mice showed potent neutralising activity against several clinically relevant forms of S. aureus infection.

Vaccines 59

Vaccines Immunity Immunization 59

RX Note

JANUARY 11, 2024

Evaporative DED Increased evaporative loss from the ocular surface due to meibomian gland dysfunction, structural abnormalities of eyelid position, decreased blink function, topical medicated or preserved eye drop use, chronic contact lens wear and ocular allergy syndrome. Clinical Features Both eyes are usually affected.

Diabetes 52

Diabetes Dosage Chemotherapy Community Pharmacies 52

European Pharmaceutical Review

JULY 5, 2022

Clinical outcomes (ie, prevention of HAE attacks in children) were measured as a secondary objective using descriptive statistics. The SPRING study trial results were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022. .

Labelling 95

Labelling 95

European Pharmaceutical Review

MAY 19, 2023

The ATTACK trial was done at 59 clinical sites in 16 countries with adults aged 18 years or older. Mortality due to multiple causes after 28 days was 12 of 63 (19 percent) in the sulbactam–durlobactam group. In the colistin group, the mortality was 32 percent.

Hospitals 104

Hospitals Medical Schools 104

Express Pharma

JUNE 18, 2023

Alkem Laboratories has launched the “Stop Sneeze to Wheeze” awareness initiative on World Allergy Week to raise awareness about the coexistence of allergic rhinitis and asthma – One Airway, One Disease. Alkem has also launched the Healthy Lungs portal ( www.thehealthylungs.com ) – a knowledge repository on lung diseases.

96

96

pharmaphorum

NOVEMBER 16, 2022

There’s plenty in the pipeline to entice a potential buyer, however, including several mid-stage clinical candidates, such as EPO inhibitor LKA651 for diabetic retinopathy, Factor B inhibitor iptacopan for AMD, and gene therapy PPY988 for geographic atrophy.

Biosimilars 123

Biosimilars Diabetes 123

RX Note

DECEMBER 26, 2023

Do not use with sulfa allergy or G6PD deficiency (due to haemolysis risk). NOTE: Fluid-filled blisters protect against infection, hence do not break blisters. If a blister breaks, clean the area with water (mild soap is optional). Apply an antibiotic ointment (e.g. mupirocin, bacitracin or polymyxin B).

Mayo Clinic 52

Mayo Clinic Diabetes Community Pharmacies 52

Pharma Mirror

DECEMBER 1, 2021

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored a randomized, double-blind, placebo-controlled clinical trial that included 969. The post Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19 appeared first on Pharma Mirror Magazine.

Immunity 52

Immunity Immunization Hospitals 52

Express Pharma

JUNE 15, 2023

Some candidates have already reached clinical development. The first mRNA-based universal vaccine, H1ssF-3928 mRNA-LNP, which was designed by the Vaccine Research Centre (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), has also recently advanced to Phase I clinical development in the US.

Vaccines 93

Vaccines Immunity Immunization Hospitals 93

Pharmaceutical Technology

AUGUST 1, 2022

The company will jointly design and analyse messenger ribonucleic acid (mRNA) Covid-19 vaccines in partnership with the NIH unit National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC). The human health product candidates of GreenLight are currently in the pre-clinical stage.

Vaccines 98

Vaccines Immunity Immunization 98

RX Note

JUNE 21, 2023

Introduction Clinical pharmacy encourages pharmacists and pharmacy support staff to shift their focus from product orientation to more direct engagement with patients , to maximise the benefits that individuals obtain from the medicines they take. Identify if there is any known food or drug allergy.

Hospitals 52

Hospitals Patient Counseling Inpatient Dosage 52

ALiEM - Pharm Pearls

APRIL 17, 2023

The patient states symptoms started 2-3 months ago and he initially thought symptoms were due to allergies and recalls rubbing his eye a lot. The clinical hallmark of keratoconus is the cone-like protrusion of the cornea. View other cases from this Clinical Image Series on ALiEM. Case Question: What is the classic exam finding?

130

130

Pharmaceutical Technology

SEPTEMBER 16, 2022

The latest conditional recommendation is based on the final data from the SOLIDARITY clinical trial, which was sponsored by the WHO. These results are in line with those obtained from the placebo-controlled, double-blind ACTT-1 trial of the National Institute of Allergy and Infectious Diseases.

Hospitals 110

Hospitals 110

pharmaphorum

NOVEMBER 11, 2022

Leading with practical insights from the best in the industry, the 4th Annual Inflammasome Therapeutics Summit is returning in person on November 29 – December 1 to Boston to equip you with the knowledge and connections to propel the next frontier of inflammasome therapeutics from pipeline to clinical and commercial reality.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Intravacc has received a contract worth $14.6m Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccines 59

Vaccines Immunity Immunization 59

European Pharmaceutical Review

JULY 13, 2022

The US National Institute of Allergy and Infectious Diseases (NIAID) has launched a Phase I clinical trial to evaluate a messenger RNA (mRNA) vaccine developed to prevent infection with Nipah virus. NIAID is sponsoring the Phase 1 study ( NCT05398796 ), which is being conducted at the NIH Clinical Center in Bethesda, Maryland. .

Vaccines 83

Vaccines Immunity Immunization 83

pharmaphorum

JANUARY 18, 2021

Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. The clinic in question switched to another lot of Moderna vaccine after closing for a few hours.

Vaccines 135

Vaccines Adverse Reactions 135

Pharmacy Joe

MAY 7, 2023

A recent abstract presented at the CHEST Congress and published in the Journal CHEST June 2020 highlighted this clinical dilemma. The authors describe the case of a 54-year-old male with a history of shellfish allergy who presented to the emergency department with dyspnea, dysphagia and urticaria shortly after ingesting shellfish.

Inpatient 52

Inpatient 52

Pharmacy Joe

MAY 7, 2023

A recent abstract presented at the CHEST Congress and published in the Journal CHEST June 2020 highlighted this clinical dilemma. The authors describe the case of a 54-year-old male with a history of shellfish allergy who presented to the emergency department with dyspnea, dysphagia and urticaria shortly after ingesting shellfish.

Inpatient 52

Inpatient 52

ALiEM - Pharm Pearls

FEBRUARY 24, 2023

Annals of Allergy, Asthma & Immunology. The Journal of Allergy and Clinical Immunology. Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue. 2007;99(4):306-313. PMID: 17941276 Dachman WD, Bedarida G, Blaschke TF, Hoffman BB. 1994;93(3):606-614.

Labelling 173

Labelling 173

Pharma Mirror

DECEMBER 4, 2020

According to Mayo Clinic, the benefits of supplements specifically apply to pregnant people (subject to doctor’s recommendation), over the age of 50, who have food allergies or digestive conditions or miss large food groups in their diet.

Mayo Clinic 52

Mayo Clinic 52

RX Note

NOVEMBER 3, 2023

Allergy to cow's milk protein is distinct to lactose intolerance. Symptoms of cow's milk allergy include hives, blotchy skin rashes, facial swelling, diarrhoea and wheeze; anaphylaxis may occur. Cow's milk allergy is common in infancy (2%), but most children outgrow it by 3 or 4 years of age; it is rare in adulthood.

Clinic Management 40

Clinic Management Documentation Community Pharmacies 40

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. DBV says it plans to request a meeting with the FDA to discuss its comments in the CRL as well, as that may be needed in another clinical trial to support another refiling. “We

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

AUGUST 9, 2023

In REMIX-2, the clinical trial enrolled 455 participants with CSU. The REMIX data for Novartis’ novel BTK inhibitor will be presented at an upcoming medical meeting. The pharmaceutical company announced that it plans to submit to global health authorities in 2024. There were 470 participants in the REMIX-1 study.

Immunity 73

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 73

pharmaphorum

NOVEMBER 9, 2022

The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted by 16 to one that PT027 should be approved for use in adults. And for younger children the vote was 16 to one against, mainly on the grounds that there were too few patients in these age brackets in AZ’s clinical trials to give a meaningful view of efficacy.

Labelling 57

Labelling 57

Putting Patients First Blog

APRIL 11, 2023

The FDA’s processes for assessing a drug’s or treatment’s benefits and risks are rigorous, involving extensive lab and clinic testing. For decades, the FDA has ensured the safety of drugs and treatments in the United States. The results are reviewed by experts in science and medicine before a drug or treatment is approved.

Diabetes 75

Diabetes 75

pharmaphorum

JANUARY 12, 2023

Avillion – clinical co-development partner with AZ – conducted the global phase 3 trial of over 4,000 patients across four studies (including the MANDALA and DENALI trials). The new approval continues the company’s unmarred success rate in clinical co-development partnerships across multiple therapeutic areas.

52

52

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. Access the official agenda for more information.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

pharmaphorum

FEBRUARY 10, 2021

Hear from Siolta Therapeutics a nd ParetoBio in developing therapeutic treatments for allergies. Access the official agenda for more information.

97

97